冠心病患者冠脉斑块稳定性与血小板趋化因子水平的关系

doi:10.3969/j.issn.1671-7171.2022.09.014

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (1233 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要【目的】探讨冠心病(CHD)患者冠脉斑块稳定性与血小板趋化因子水平的相关性。【方法】选取2020年6月至2022年2月中国人民解放军空军第九八六医院收治的60例CHD患者(观察组),同时根据冠脉斑块稳定性进一步分为稳定组(n=35)和不稳定组(n=25),另选取同期体检健康的60例健康志愿者为研究对象(对照组)。比较观察组与对照组血小板趋化因子16(CXCL16)、血小板趋化因子4(CXCL4)、血小板与淋巴细胞比值(PLR)、Fractalkine,比较观察组不同斑块稳定性患者的CXCL16、CXCL4、PLR、Fractalkine指标,采用受试者工作特征曲线(ROC曲线)评估CXCL16、CXCL4、PLR、Fractalkine预测CHD患者斑块不稳定的效能。【结果】观察组CXCL16、CXCL4、PLR、Fractalkine水平显著高于对照组,差异有统计学意义(P<0.05)。不稳定组CXCL16、CXCL4、PLR、Fractalkine水平高于稳定组,差异有统计学意义(P<0.05)。ROC曲线分析显示,CXCL16、CXCL4、Fractalkine、PLR预测斑块不稳定的最佳截断值分别为2.766 μg/L、0.956 ng/mL、61.064 ng/mL、111.820,CXCL16曲线下面积为0.975,敏感度、特异性均较高,分别为0.920、0.943。【结论】CXCL16、CXCL4、PLR、Fractalkine水平均与CHD患者的冠脉斑块稳定性密切相关,有助于医护人员辨识CHD患者冠脉斑块的稳定性。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	王海强
	王磊

关键词 ：冠心病, 斑块,动脉粥样硬化, 血小板因子4

Abstract：【Objective】 To investigate the relationship between the stability of coronary plaque and the level of platelet chemokines in patients with coronary heart disease (CHD). 【Methods】 From June 2020 to February 2022, 60 CHD patients (observation group) admitted to the 986 Hospital of the Air Force of the People's Liberation Army of China were selected. At the same time, according to the stability of coronary plaque, they were further divided into stable group (n=35) and unstable group (n=25). In addition, 60 healthy volunteers who were healthy during the same period were selected as the study subjects (control group). Platelet chemokine 16 (CXCL16), platelet chemokine 4 (CXCL4), platelet lymphocyte ratio (PLR) and Fractalkine were compared between the observation group and the control group. CXCL16, CXCL4, PLR, Fractalkine indexes of patients with different plaque stability in the observation group were compared. The receiver operating characteristic curve (ROC curve) was used to evaluate the efficacy of CXCL16, CXCL4, PLR, Fractalkine in predicting plaque instability in CHD patients.【Results】 The levels of CXCL16, CXCL4, PLR and Fractalkine in the observation group were significantly higher than those in the control group (P<0.05). The levels of CXCL16, CXCL4, PLR and Fractalkine in the unstable group were higher than those in the stable group (P<0.05). ROC curve analysis shows that the best cut-off values of CXCL16, CXCL4, PLR and Fractalkine for predicting plaque instability were 2.766 μg/L, 0.956 ng/mL, 111.820, 61.064 ng/mL respectively. The area under the CXCL16 curve was 0.975, with high sensitivity and specificity, 0.920 and 0.943 respectively. 【Conclusion】 The levels of CXCL16, CXCL4, PLR and Fractalkine are closely related to the stability of coronary plaque in CHD patients, which is helpful for doctors and nurses to identify the stability of coronary plaque in CHD patients.

Key words： Coronary Disease Plaque,Atherosclerotic Platelet Factor 4

收稿日期: 2022-03-10

中图分类号:

R541.4

基金资助:陕西省分子心脏病学重点实验室开放项目(KLMC-2018-02)

通讯作者: **E-mail:824826316@qq.com

引用本文:

王海强, 王磊. 冠心病患者冠脉斑块稳定性与血小板趋化因子水平的关系[J]. 医学临床研究, 2022, 39(9): 1329-1331.
WANG Hai-qiang, WANG Lei. Relationship between Coronary Plaque Stability and Platelet Chemokines in Patients with Coronary Heart Disease. JOURNAL OF CLINICAL RESEARCH, 2022, 39(9): 1329-1331.

链接本文:

http://journal07.magtech.org.cn/yxlcyj/CN/10.3969/j.issn.1671-7171.2022.09.014 或 http://journal07.magtech.org.cn/yxlcyj/CN/Y2022/V39/I9/1329

[1] SIASOS G,SARA J D,ZAROMYTIDOU M,et al.Local low shear stress and endothelialdysfunction in patients with nonobstructive coronary atherosclerosis[J].JACC Cardiovasc Interv,2018,71(19):2092-2102.
[2] YOON Y E,BASKARAN L,LEE B C,et al.Differential progression of coronary atherosclerosis according to plaque composition:a cluster analysis of PARADIGM registry data[J].Sci Rep,2021,11(1):1-12.
[3] 李树花,吉宇霞,楚振荣,等.急性脑梗死患者血清CXCL16水平与颈动脉粥样硬化的相关性及临床分析[J].脑与神经疾病杂志,2020,28(1):41-44.
[4] 孙鲲,宋文超,周文恒.益气活血通脉法联合阿托伐他汀对高血压病颈动脉粥样硬化患者血清脂蛋白相关磷脂酶A2、趋化因子配体与氧化应激指标影响[J].辽宁中医药大学学报,2020,22(4):166-169.
[5] 张新,王玲,王世蓉,等.中性粒细胞与淋巴细胞比值、血小板与淋巴细胞比值及同型半胱氨酸与2型糖尿病患者冠心病的关系研究[J].实用心脑肺血管病杂志,2019,27(6):44-47.
[6] 王晓会.阿托伐他汀钙联合丹参川芎嗪注射液治疗冠心病心绞痛的临床疗效及对血清Fractalkine和血小板活化因子水平的影响[J].广西医科大学学报,2019,36(3):435-438.
[7] 中华医学会,中华医学会杂志社,中华医学会全科医学分会,等.冠心病心脏康复基层指南(2020年)[J].中华全科医师杂志,2021,20(2):150-165.
[8] 胡碧仙.彩色多普勒超声诊断颈动脉硬化斑块的价值[J].中国基层医药,2014,21(2):278-279.
[9] HILLARD K,THOMPSON R C,TRUMBLE B C,et al.Coronary atherosclerosis in indigenous South American Tsimane:a cross-sectional cohort study[J].Lancet,2018,389(10080):1730-1739.
[10] 董敏,邹彤,李雨薇,等.心房颤动合并冠心病患者的抗栓治疗现状和血栓栓塞事件分析[J].中国循环杂志,2018,33(9):856-860.
[11] 罗永百,郑树慧,王燕妮.CXCL16在急性冠状动脉综合征患者外周血中的表达及其与冠状动脉病变的相关性分析[J].临床心血管病杂志,2019,35(7):624-627.
[12] 陈美凤,魏芳晶.CXCL16及其受体与冠状动脉粥样硬化的关系[J].心脑血管病防治,2019,19(1):84-86.
[13] 赵鹏,张彦周,李爱琴,等.冠心病病人血清CXCL4和CXCL12水平与冠状动脉粥样斑块稳定性的关系[J].中西医结合心脑血管病杂志,2019,17(20):3162-3164.
[14] 朱勇,胡成平,杜俣,等.血小板与淋巴细胞比值和青年冠状动脉粥样硬化性心脏病患者冠状动脉病变严重程度的相关性研究[J].中国医药,2018,13(11):1624-1627.
[15] 邓静,王春莲,文俊杰,等.普萘洛尔联合硝酸异山梨酯对冠心病心绞痛患者Obestatin、tPAI-1、Fractalkine水平的影响[J].中国医药导报,2020,17(32):56-59.